Changes for page Torrent Pharmaceuticals Ltd

Last modified by Asif Farooqui on 2021/09/20 18:50

From version < 8.1 >

edited by Asif Farooqui
on 2021/09/20 18:42

To version < 8.2 >

edited by Asif Farooqui
on 2021/09/20 18:44

< >

Change comment: There is no comment for this version

Raw
Rendered

Summary

Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

@@ -330,12
+330,24 @@
  Torrent Pharma is one of the front-runners in the Indian pharmaceuticals industry having presence in domestic as well as International markets. The Company has subsidiaries across the globe as under. The Company also has major commercial presence in other countries mainly covering Southeast Asia, Africa and the Middle East.
--<table>
++(% style="width:736px" %)
++|(% style="width:233px" %)**Revenue (in crores)**|(% style="width:119px" %)**2020-21**|(% style="width:81px" %) |(% style="width:117px" %)**2019-20**|(% style="width:91px" %) |(% style="width:92px" %)**Growth**
++|(% style="width:233px" %) |(% style="width:119px" %)**Amount**|(% style="width:81px" %)** Share**|(% style="width:117px" %)**Amount **|(% style="width:91px" %)**Share**|(% style="width:92px" %)**%**
++|(% style="width:233px" %)**India**|(% style="width:119px" %)3,739|(% style="width:81px" %)47%|(% style="width:117px" %)3,517|(% style="width:91px" %)44%|(% style="width:92px" %)6%
++|(% style="width:233px" %)**USA**|(% style="width:119px" %)1,261|(% style="width:81px" %)16%|(% style="width:117px" %)1,523|(% style="width:91px" %)19%|(% style="width:92px" %)-17%
++|(% style="width:233px" %)**Germany**|(% style="width:119px" %)1,038|(% style="width:81px" %)13%|(% style="width:117px" %)947|(% style="width:91px" %)12%|(% style="width:92px" %)10%
++|(% style="width:233px" %)**Brazil**|(% style="width:119px" %)630|(% style="width:81px" %)8%|(% style="width:117px" %)715|(% style="width:91px" %)9%|(% style="width:92px" %)-12%
++|(% style="width:233px" %)**Other countries**|(% style="width:119px" %)820|(% style="width:81px" %)10%|(% style="width:117px" %)766|(% style="width:91px" %)10%|(% style="width:92px" %)7%
++|(% style="width:233px" %)**CRAMS/others**|(% style="width:119px" %)517|(% style="width:81px" %)6%|(% style="width:117px" %)472|(% style="width:91px" %)6%|(% style="width:92px" %)10%
++|(% style="width:233px" %)**Total**|(% style="width:119px" %)8,005|(% style="width:81px" %)100%|(% style="width:117px" %)7,939|(% style="width:91px" %)100%|(% style="width:92px" %)1%
++
++
  Torrent’s four major pharma markets are India, US, Germany and Brazil. The Company’s strategic priorities in India and Brazil continue to focus on strengthening specialties, field force productivity and new product development. These markets remain a key priority for the Company and offer higher visibility and sustainability to the business. In the US and Germany, the Company continues to focus on its new product pipeline by developing complex products.
--India
++== India ==
++
  The Indian pharmaceutical market (IPM), which is valued at more than $20 billion has demonstrated its resilience in 2020-21 during the pandemic. Over the past several years, the IPM has exhibited a strong growth trajectory and is fundamentally poised to remain a double-digit growth market owing to several demand levers over the coming years. With rising prevalence of chronic diseases, a significant push towards increasing healthcare coverage towards a large set of the population coupled with government support and insurance coverage, volume growth in the IPM in all therapies is more than likely to sustain this momentum in the near term, and even increase over the medium term. Notwithstanding the therapy specific impact that the pandemic is likely to have in the coming year 2021-22, the IPM should grow at a significantly higher rate than the previous year.
  The fiscal 2020-21 witnessed demand disruptions in several forms; lockdowns reduced patient footfalls, general infections remained low due to greater social distancing measures followed, and physician practice was impacted in the first half of the year. On the other hand, pandemic related drugs, including repurposed antivirals, multivitamins, immunity boosters and nutraceuticals saw a boost. In 2021-22, while the impact related to lockdowns may be much lower on an annual basis, the second wave of the pandemic is likely to affect overall demand in the first half of the year.
@@ -348,8
+348,9 @@
  New introductions in key therapies have been a focus area for Torrent Pharma to drive higher than market growth and it has launched a significant number of new products in 2020-21. In addition to patent expiration launches, Torrent Pharma has launched several brand extensions with first-in-India combinations for unmet needs, and this will remain a focus for the coming years. Some important new introductions in key markets were - Dapagliflozin and Rivaroxaban in the CVD therapeutic area; Brivaracetam in the CNS segment; Obeticholic Acid within the Gatro-intestinal therapy along with strengthened presence in Pain Analgesic segment through NDDS Tapentadol Nasal Spray. Tapentadol NS is Torrent’s own patented and in-house developed nasal spray for severe pain management.
--Brazil
++== Brazil ==
++
  Brazil is the largest pharmaceutical market in Latin America and the 10th largest in the world. The Brazilian pharma market is estimated to be around US$ 33.6 billion as of Dec-2019 and is expected to grow through a year-on-year growth of 6-9% over next 5 years, depending on expected improvements on macroeconomic parameters under government controls and its policies
  Brazil’s economic scenario worsened due to the pandemic. GDP in 2019-20 declined by 4.1%. Inflation is expected to remain in the range of 4% to 5% in 2021. Apart from economic impact, Brazil is still facing difficulties in implementing reforms. In 2019-20, both tax and administrative reforms were included in Congress’ agenda but are still facing resistance. Main objective of tax reform is to simplify taxation rules by implementing GST (Goods and Service Tax) whereas administrative reform is to address the fiscal imbalances and high cost of the administrative structure. Economic challenges stemming from productivity and low investments remain to be addressed by the government also through privatisation of state-owned companies.
@@ -358,8
+358,9 @@
  Among the Indian companies, in terms of value Torrent Pharma ranks No. 1, with the second largest less than half of the size of Torrent (IQVIA dataset). Currently, Torrent has commercialised 24 Branded Generics and 20 Generic products. In its Branded Generic portfolio, the Company has 11 filings awaiting approval, 23 under preparation for filing in existing business and 17 in new business. In addition, the Company has been building its portfolio in the Generic segment with parallel filings and launches of its Branded Generic products.
--USA
++== USA ==
++
  USA continues to be the largest pharmaceutical market, accounting for approximately 41% of global pharmaceutical spending. It recorded 4% CAGR for 2014-19 and is expected to grow at 3-6% CAGR to US $605-635 billion by 2023-24.
  Growth will likely be principally driven by the development and launch of innovative specialty drugs but will be partially tempered by existing drug patent expiries and cost reduction initiatives by payers
@@ -372,8
+372,9 @@
  Torrent Pharma is ranked 11 among the US Generic Indian companies and has a market share of around 13% in its covered market. Revenues from the US business were Rs 1261 crores (sales US$ 166 million) during 2020-21 as compared to Rs 1,523 crores (sales US$ 207 million) in the previous year with a de-growth of 17%.
--Germany
++== Germany ==
++
  Top 5 European markets are Germany, France, Italy, UK and Spain. Medicine spending in top 5 European countries will increase from US$ 174 billion 2018-19 to US$ 210 to US$ 240 billion in 2024. CAGR from 2019-20 to 2023-24 is expected to be 3% to 6%.
  Despite the COVID-19 disruptions, with continued support and industry resilience, the European pharma outlook for 2021 is positive. The presence of leading companies in the European region is also expected to boost the demand for pharmaceutical manufacturing.
@@ -383,69
+383,56 @@
  Germany is the 4th largest pharmaceutical market in the world and the largest in Western Europe. It is valued at around $52 billion and is expected to grow at a CAGR of 4% to 75 till 2020-24. Majority of the market is tender driven, which leads to a very competitive environment for the industry. Among the Generic players, Torrent Pharma holds 5th position with a market share of around 6.6% and is ranked first among Indian players in the German market. Revenues from Germany operations during 2020-21 were Rs 1,038 crores (sales in euro 119 milliom) with a growth of 10%.
--Financial Highlights
++[[image:TORNTPHARM8.jpg]]
--The consolidated sales and operating income for the year ended 31 March 2021, increased to Rs 8,005 crores from Rs 7,939 crores in the previous year showing a growth of 1%. The consolidated operating profit for the year was Rs 2,537 crores as against Rs 2,284 crores in the previous year registering growth of 11%. The consolidated net profit stood at Rs 1,252 crores compared to Rs 1,025 crores in the previous year registering growth of 22%.
--Torrent Pharma Q1 FY22 results
++= Financial Highlights =
--Revenues & profitability
++The consolidated sales and operating income for the year ended 31 March 2021, increased to Rs 8,005 crores from Rs 7,939 crores in the previous year showing a growth of 1%. The consolidated operating profit for the year was Rs 2,537 crores as against Rs 2,284 crores in the previous year registering growth of 11%. The consolidated net profit stood at Rs 1,252 crores compared to Rs 1,025 crores in the previous year registering growth of 22%.
--[[https:~~/~~/torrentpharma.com/pdf/investors/Press_Release_Torrent_Pharma_Results_21-22.pdf>>url:https://torrentpharma.com/pdf/investors/Press_Release_Torrent_Pharma_Results_21-22.pdf]]
--Revenue at Rs. 2,134 crores up by 4%
++== Torrent Pharma Q1 FY22 results ==
--Gross margins : 72.4%; EBITDA margins : 34%
++**Revenues & profitability **{{footnote}}https://torrentpharma.com/pdf/investors/Press_Release_Torrent_Pharma_Results_21-22.pdf{{/footnote}}
--EBITDA at Rs. 717 crores was up by 8%
++* Revenue at Rs. 2,134 crores up by 4%
++* Gross margins : 72.4%; EBITDA margins : 34%
++* EBITDA at Rs. 717 crores was up by 8%
++* Profit before tax at Rs. 484 crores was up by 20%.
++* Net profit after tax at Rs. 330 crores was up 2.8%.
--Profit before tax at Rs. 484 crores was up by 20%.
--Net profit after tax at Rs. 330 crores was up 2.8%.
++**India**
++* India revenues at Rs 1,093 crores grew by 18%.
++* As per AIOCD data, Torrent’s Q1 FY22 growth was 24% versus IPM growth of 37%. IPM growth during the quarter includes high contribution from Covid treatments and a low base last year
++* Covid drugs: Torrent has launched baricitinib during the quarter and is currently conducting clinical trials for molnupiravir; more partnerships under evaluation to widen covid portfolio
++* PCPM for the quarter was Rs 10 lakhs with an MR strength of 3,600
++* Torrent has launched its Trade Generics division during the quarter.
--India
--India revenues at Rs 1,093 crores grew by 18%.
++**United States**
--As per AIOCD data, Torrent’s Q1 FY22 growth was 24% versus IPM growth of 37%. IPM growth during the quarter includes high contribution from Covid treatments and a low base last year
++* US revenues at Rs 266 crores, were down by 29%.
++* Constant currency sales were $36 million.
++* Sales were lower due to price erosion in the base business and lack of new approvals pending re-inspection of facilities.
++* As on June 30, 2021, 54 ANDAs were pending for approval with USFDA and 7 tentative approvals were received, including 1 tentative approval received during the quarter.
--Covid drugs: Torrent has launched baricitinib during the quarter and is currently conducting clinical trials for molnupiravir; more partnerships under evaluation to widen covid portfolio
--PCPM for the quarter was Rs 10 lakhs with an MR strength of 3,600
++**Brazil**
--Torrent has launched its Trade Generics division during the quarter.
++* Brazil revenues at Rs 153 crores, were up by 9%
++* Constant currency sales at R$ 108 million, was up by 14% versus covered market growth of 12%
++* Growth was driven by growth momentum in boththe branded and generic segment. New products have contributed to 3% growth.
--United States
++**Germany**
--US revenues at Rs 266 crores, were down by 29%.
++* Germany revenues at Rs 260 crores were up by 5%
++* Constant currency sales were Euro 29 million with flat growth.
++* Second wave of Covid and related lockdowns impacted the market growth during the quarter.
--Constant currency sales were $36 million.
--Sales were lower due to price erosion in the base business and lack of new approvals pending re-inspection of facilities.
++= References =
--As on June 30, 2021, 54 ANDAs were pending for approval with USFDA and 7 tentative approvals were received, including 1 tentative approval received during the quarter.
--
--
--Brazil
--
--Brazil revenues at Rs 153 crores, were up by 9%
--
--Constant currency sales at R$ 108 million, was up by 14% versus covered market growth of 12%
--
--Growth was driven by growth momentum in boththe branded and generic segment. New products have contributed to 3% growth.
--
--
--Germany
--
--Germany revenues at Rs 260 crores were up by 5%
--
--Constant currency sales were Euro 29 million with flat growth.
--
--Second wave of Covid and related lockdowns impacted the market growth during the quarter.
--
--
--References
--
  {{putFootnotes/}}

Applications

More applications

Recently Visited

Analysts

Photo	Name
	kayla hamelton
	Michael G
	Jeanpierre Pozo
	Robert Lakin
	Erich Richards
	Jason Adams
	Thomas Niel
	Md. Touhidul Islam
	Ajit Singh
	Buck Winston
	Asif Farooqui
	Wilton Risenhoover

View All

Recently Modified

This site is funded and maintained by Fintel.io

XWiki 12.2.1